Drug Profile
Encorafenib - Array BioPharma/Ono Pharmaceutical/Pierre Fabre
Alternative Names: BRAFTOVI; LGX-818; NVP-LGX818; NVP-LGX818-NXA; ONO-7702; PF 07263896; W-0090Latest Information Update: 20 Mar 2024
Price :
$50
*
At a glance
- Originator Novartis Pharmaceuticals Corporation
- Developer Array BioPharma; German Cancer Research Center; Merck KGaA; National Cancer Institute (USA); Novartis Pharmaceuticals Corporation; Ono Pharmaceutical; Pfizer; Pierre Fabre; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; University of Heidelberg
- Class Amines; Antineoplastics; Carbamates; Chlorinated hydrocarbons; Fluorinated hydrocarbons; Pyrazoles; Pyrimidines; Small molecules; Sulfonamides
- Mechanism of Action Proto oncogene protein b raf inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Colorectal cancer; Malignant melanoma
- Registered Non-small cell lung cancer
- Preregistration Thyroid cancer
- Phase II Brain metastases; Glioma; Haematological malignancies; Multiple myeloma; Solid tumours
- Phase I Cancer
Most Recent Events
- 08 Mar 2024 Pierre Fabre completes a Phase-III clinical trials in Malignant melanoma (Adjuvant therapy, Combination therapy) in Italy (PO) (EudraCT2021-000743-41)
- 28 Nov 2023 Ono Pharmaceutical plans to file regulatory submissions for Colorectal cancer (Combination therapy, First-line therapy) in Japan (PO), by 2024
- 02 Nov 2023 Efficacy data from a phase II PHAROS trial in Non-small cell lung cancer released by Pierre Fabre